1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs
  4. >>Emerging Company Profiles

Freya Biosciences Has $38m And A Plan To Change Women’s Lives

 
• By Elizabeth Cairns

Emerging Company Profile: Armed with a new tranche of funding, the Danish group is aiming to improve the lot of infertile couples by altering the microbiome of patients with dysbiosis.  

Emerging Company Profile: Freya Biosciences
• Source: Shutterstock

Freya Biosciences closed a $38m series A financing last month and will be putting the cash towards the development of its vaginal microbial immunotherapeutic FB101, initially for the treatment of infertility.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Emerging Company Profiles

Immusoft Goes For Cell Therapy Plan ‘B’

 
• By Alaric DeArment

Emerging Company Profile: CEO Sean Ainsworth spoke with Scrip about how the company is developing B-cell therapies to treat a range of diseases, starting with MPS I.

Sanofi-Backed Resalis Brings MicroRNA To Obesity

 
• By Elizabeth Cairns

Emerging Company Profile: Resalis will soon start human trials of an oligonucleotide targeting a microRNA that is overexpressed in obese mice, but much remains to be proven in humans.

Volastra Aims To Terminate Cancer Relying On Chromosomal Instability

 
• By Jessica Merrill

Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.

Seraxis Takes Its Islet Cell Tech Into The Clinic

 
• By Elizabeth Cairns

Emerging Company Profile: The Maryland-based biotech is working on a functional cure for type 1 diabetes that is similar to Vertex’s VX-880 – but with some key differences.

More from Start-Ups & SMEs

Novo Adds Lexicon’s Novel Obesity Drug To Deal Flurry

 
• By Andrew McConaghie

The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.

Major Cash Injection Advances Augustine’s HDAC6 Hopes

 
• By Kevin Grogan

The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.

Roche Adds To Its Antibody Armoury With OBT Alliance

 
• By Kevin Grogan

Deal Snapshot: The antibody-drug conjugate field continues one of the hottest dealmaking spaces and Roche continues to invest heavily. Its latest pact could be transformative for the UK firm which already has a decent number of big pharma partners.